LU91680I2 - "rilonacept et ses dérivés pharmaceutiquement acceptables (ARCALYSR)" - Google Patents

"rilonacept et ses dérivés pharmaceutiquement acceptables (ARCALYSR)"

Info

Publication number
LU91680I2
LU91680I2 LU91680C LU91680C LU91680I2 LU 91680 I2 LU91680 I2 LU 91680I2 LU 91680 C LU91680 C LU 91680C LU 91680 C LU91680 C LU 91680C LU 91680 I2 LU91680 I2 LU 91680I2
Authority
LU
Luxembourg
Prior art keywords
arcalysr
rilonacept
pharmaceutically acceptable
acceptable derivatives
fusion polypeptide
Prior art date
Application number
LU91680C
Other languages
English (en)
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of LU91680I2 publication Critical patent/LU91680I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Rheumatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Vehicle Body Suspensions (AREA)
  • Sewing Machines And Sewing (AREA)
  • Electrical Discharge Machining, Electrochemical Machining, And Combined Machining (AREA)
LU91680C 2002-10-28 2010-04-21 "rilonacept et ses dérivés pharmaceutiquement acceptables (ARCALYSR)" LU91680I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/282,162 US6927044B2 (en) 1998-09-25 2002-10-28 IL-1 receptor based cytokine traps
PCT/US2003/033718 WO2004039951A2 (fr) 2002-10-28 2003-10-24 Antagonistes a base de recepteurs d'il-1 et procede de fabrication et d'utilisation

Publications (1)

Publication Number Publication Date
LU91680I2 true LU91680I2 (fr) 2010-06-21

Family

ID=32228782

Family Applications (1)

Application Number Title Priority Date Filing Date
LU91680C LU91680I2 (fr) 2002-10-28 2010-04-21 "rilonacept et ses dérivés pharmaceutiquement acceptables (ARCALYSR)"

Country Status (18)

Country Link
US (4) US6927044B2 (fr)
EP (1) EP1572967B1 (fr)
JP (1) JP4387309B2 (fr)
CN (1) CN1878871B (fr)
AT (1) ATE420970T1 (fr)
AU (1) AU2003284895B2 (fr)
BR (1) BRPI0315652B8 (fr)
CA (1) CA2502385C (fr)
CY (2) CY1110675T1 (fr)
DE (1) DE60325892D1 (fr)
DK (1) DK1572967T3 (fr)
ES (1) ES2320338T3 (fr)
IL (1) IL168050A (fr)
LU (1) LU91680I2 (fr)
MX (1) MXPA05004333A (fr)
PT (1) PT1572967E (fr)
SI (1) SI1572967T1 (fr)
WO (1) WO2004039951A2 (fr)

Families Citing this family (185)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6927044B2 (en) * 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US20090137416A1 (en) 2001-01-16 2009-05-28 Regeneron Pharmaceuticals, Inc. Isolating Cells Expressing Secreted Proteins
WO2004100987A2 (fr) * 2003-05-06 2004-11-25 Regeneron Pharmaceuticals, Inc. Procede d'utilisation d'antagonistes de l'il1 pour le traitement d'hyperplasie neointimale
TWI353991B (en) 2003-05-06 2011-12-11 Syntonix Pharmaceuticals Inc Immunoglobulin chimeric monomer-dimer hybrids
HUE029951T2 (en) * 2003-07-28 2017-04-28 Genentech Inc Reduction of Protein A Dissolution in Protein A Affinity Chromatography
US20050129685A1 (en) * 2003-09-18 2005-06-16 Jingtai Cao Use of IL-1 blockers to prevent corneal inflammation and neovascularization
WO2005037869A2 (fr) * 2003-10-15 2005-04-28 Applera Corporation Methode de diminution de lixiviat de milieux d'affinite a la proteine a
EP1723173B1 (fr) * 2004-02-27 2008-05-14 Regeneron Pharmaceuticals, Inc. Polypeptides specifiques d'il-4/il-13 et utilisations therapeutiques associees
AU2005249570B2 (en) * 2004-06-04 2011-06-16 Regeneron Pharmaceuticals, Inc. Methods of using IL-1 antagonists to treat autoinflammatory disease
US7572893B2 (en) * 2004-08-17 2009-08-11 Regeneron Pharmaceuticals, Inc. IL-1 antagonist formulations
AU2005277357B2 (en) * 2004-08-17 2011-08-04 Regeneron Pharmaceuticals, Inc. IL-1 antagonist formulations
US7655758B2 (en) 2004-08-17 2010-02-02 Regeneron Pharmaceuticals, Inc. Stable liquid IL-1 antagonist formulations
US20060160737A1 (en) * 2005-01-14 2006-07-20 Allen Radin Methods of using IL-1 antagonists to treat polymyalgia rheumatica and giant cell arteritis
US20060171948A1 (en) * 2005-02-02 2006-08-03 Weinstein Steven P Methods of using IL-1 antagonists to reduce C-reactive protein
PT1928910E (pt) * 2005-08-16 2014-03-06 Hanmi Science Co Ltd Um método para produção em massa de uma região fc da imunoglobulina com deleção dos resíduos de metionina inicial
EP1940880A2 (fr) * 2005-10-14 2008-07-09 Novo Nordisk A/S Traitement du diabete a l'aide d'inhibiteurs de l'il-1
SI2944306T1 (sl) 2006-06-16 2021-04-30 Regeneron Pharmaceuticals, Inc. Formulacije antagonista VEGF, primerne za intravitrealno dajanje
US7632490B2 (en) * 2006-10-20 2009-12-15 Regeneron Pharmaceuticals, Inc. Use of IL-1 antagonists to treat gout
MX2009004051A (es) * 2006-10-20 2009-05-11 Regeneron Pharma Uso de antagonistas de il-1 para tratar gota y pseudo gota.
JP5272735B2 (ja) * 2007-01-30 2013-08-28 国立大学法人 新潟大学 生物学的製剤
MY161564A (en) 2007-08-10 2017-04-28 Regeneron Pharma High affinity human antibodies to human nerve growth factor
AU2008289552B2 (en) * 2007-08-16 2014-10-09 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of inflammation of ocular and adnexal tissues
US8753690B2 (en) * 2008-02-27 2014-06-17 Biomet Biologics, Llc Methods and compositions for delivering interleukin-1 receptor antagonist
EP2620139B1 (fr) 2008-02-27 2016-07-20 Biomet Biologics, LLC Solutions riches d'un antagoniste du récepteur de l'interleukine-1
US8828354B2 (en) * 2008-03-27 2014-09-09 Warsaw Orthopedic, Inc. Pharmaceutical gels and methods for delivering therapeutic agents to a site beneath the skin
US9072727B2 (en) 2008-04-18 2015-07-07 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of degenerative disc disease
US9132119B2 (en) 2008-04-18 2015-09-15 Medtronic, Inc. Clonidine formulation in a polyorthoester carrier
US9289409B2 (en) * 2008-04-18 2016-03-22 Warsaw Orthopedic, Inc. Sulindac formulations in a biodegradable material
US8883768B2 (en) * 2008-04-18 2014-11-11 Warsaw Orthopedic, Inc. Fluocinolone implants to protect against undesirable bone and cartilage destruction
US8557273B2 (en) * 2008-04-18 2013-10-15 Medtronic, Inc. Medical devices and methods including polymers having biologically active agents therein
US9132085B2 (en) * 2008-04-18 2015-09-15 Warsaw Orthopedic, Inc. Compositions and methods for treating post-operative pain using clonidine and bupivacaine
US20090264477A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc., An Indiana Corporation Beta adrenergic receptor agonists for treatment of pain and/or inflammation
US20090264489A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Method for Treating Acute Pain with a Formulated Drug Depot in Combination with a Liquid Formulation
US8420114B2 (en) * 2008-04-18 2013-04-16 Warsaw Orthopedic, Inc. Alpha and beta adrenergic receptor agonists for treatment of pain and / or inflammation
US8956636B2 (en) 2008-04-18 2015-02-17 Warsaw Orthopedic, Inc. Methods and compositions for treating postoperative pain comprosing ketorolac
USRE48948E1 (en) 2008-04-18 2022-03-01 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable polymer
US8629172B2 (en) 2008-04-18 2014-01-14 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising clonidine
US8846068B2 (en) 2008-04-18 2014-09-30 Warsaw Orthopedic, Inc. Methods and compositions for treating post-operative pain comprising a local anesthetic
US8722079B2 (en) 2008-04-18 2014-05-13 Warsaw Orthopedic, Inc. Methods for treating conditions such as dystonia and post-stroke spasticity with clonidine
US8889173B2 (en) 2008-04-18 2014-11-18 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of pain and/or inflammation
US20090263451A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedic, Inc. Anti-Inflammatory and/or Analgesic Agents for Treatment of Myofascial Pain
US9125917B2 (en) * 2008-04-18 2015-09-08 Warsaw Orthopedic, Inc. Fluocinolone formulations in a biodegradable polymer carrier
US8956641B2 (en) 2008-04-18 2015-02-17 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for treatment of inflammatory diseases
US20090263443A1 (en) * 2008-04-18 2009-10-22 Warsaw Orthopedics, Inc. Methods for treating post-operative effects such as spasticity and shivering with clondine
US20100016265A1 (en) * 2008-07-16 2010-01-21 Qaiser Yusuf Anti-inflammatory composition and method for preparation
US20100015049A1 (en) * 2008-07-16 2010-01-21 Warsaw Orthopedic, Inc. Methods and compositions for treating postoperative pain comprising nonsteroidal anti-inflammatory agents
US9492375B2 (en) 2008-07-23 2016-11-15 Warsaw Orthopedic, Inc. Foam carrier for bone grafting
US8377444B2 (en) * 2008-08-01 2013-02-19 Axis Inc. Therapeutic agent or preventive agent for osteoarthritis
US9161903B2 (en) * 2008-10-31 2015-10-20 Warsaw Orthopedic, Inc. Flowable composition that hardens on delivery to a target tissue site beneath the skin
AU2010203425B2 (en) 2009-01-09 2015-04-09 The Schepens Eye Research Institute, Inc. Therapeutic compositions for treatment of corneal disorders
US20100228097A1 (en) * 2009-03-04 2010-09-09 Warsaw Orthopedic, Inc. Methods and compositions to diagnose pain
US20100226959A1 (en) * 2009-03-04 2010-09-09 Warsaw Orthopedic, Inc. Matrix that prolongs growth factor release
US20100239632A1 (en) 2009-03-23 2010-09-23 Warsaw Orthopedic, Inc. Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue
US8617583B2 (en) 2009-07-17 2013-12-31 Warsaw Orthopedic, Inc. Alpha adrenergic receptor agonists for prevention or treatment of a hematoma, edema, and/or deep vein thrombosis
US8231891B2 (en) 2009-07-31 2012-07-31 Warsaw Orthopedic, Inc. Implantable drug depot for weight control
WO2011031553A2 (fr) 2009-08-27 2011-03-17 Biomet Biologics, Llc Dispositif implantable pour la production d'antagoniste de récepteur d'interleukine-1
US20110052561A1 (en) 2009-08-27 2011-03-03 Biomet Biologics,LLC Osteolysis treatment
KR20120082906A (ko) 2009-09-30 2012-07-24 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 자가포식현상-향상 유전자 생성물의 조절을 통한 자가포식현상의 조절 방법
US20110097375A1 (en) 2009-10-26 2011-04-28 Warsaw Orthopedic, Inc. Formulation for preventing or reducing bleeding at a surgical site
US20110097380A1 (en) * 2009-10-28 2011-04-28 Warsaw Orthopedic, Inc. Clonidine formulations having antimicrobial properties
US9504698B2 (en) * 2009-10-29 2016-11-29 Warsaw Orthopedic, Inc. Flowable composition that sets to a substantially non-flowable state
US8597192B2 (en) 2009-10-30 2013-12-03 Warsaw Orthopedic, Inc. Ultrasonic devices and methods to diagnose pain generators
US8475824B2 (en) 2010-01-26 2013-07-02 Warsaw Orthopedic, Inc. Resorbable matrix having elongated particles
US8758791B2 (en) 2010-01-26 2014-06-24 Warsaw Orthopedic, Inc. Highly compression resistant matrix with porous skeleton
US9486500B2 (en) 2010-01-28 2016-11-08 Warsaw Orthopedic, Inc. Osteoimplant and methods for making
US9125902B2 (en) * 2010-01-28 2015-09-08 Warsaw Orthopedic, Inc. Methods for treating an intervertebral disc using local analgesics
US9050274B2 (en) * 2010-01-28 2015-06-09 Warsaw Orthopedic, Inc. Compositions and methods for treating an intervertebral disc using bulking agents or sealing agents
JO3183B1 (ar) 2010-01-29 2018-03-08 Regeneron Pharma طرق لمعالجة أمراض المناعة الذاتية مضادات dll4
JP2012246222A (ja) * 2010-01-29 2012-12-13 Axis Inc 変形性関節症治療剤または予防剤を製造するための使用
EP4450523A3 (fr) 2010-04-02 2025-03-12 Amunix Pharmaceuticals, Inc. Protéines de fusion de liaison, conjugués protéine de fusion-médicament de liaison, conjugués xten-médicament et leurs procédés de fabrication et d'utilisation
HRP20191305T1 (hr) 2010-07-09 2019-10-18 Bioverativ Therapeutics Inc. Preradive jednolančane molekule i polipeptidi izrađeni koristeći iste
SG187231A1 (en) 2010-07-29 2013-02-28 Eleven Biotherapeutics Inc Chimeric il-1 receptor type i agonists and antagonists
US8246571B2 (en) 2010-08-24 2012-08-21 Warsaw Orthopedic, Inc. Drug storage and delivery device having a retaining member
JP2013536841A (ja) 2010-09-03 2013-09-26 バイオメット、バイオロジクス、リミテッド、ライアビリティー、カンパニー インターロイキン−１受容体アンタゴニストを送達するための方法および組成物
US8740982B2 (en) 2010-10-26 2014-06-03 Kyphon Sarl Devices containing a chemonucleolysis agent and methods for treating an intervertebral disc or spinal arachnoiditis
US8404268B2 (en) 2010-10-26 2013-03-26 Kyphon Sarl Locally targeted anti-fibrotic agents and methods of use
US9414930B2 (en) 2010-10-26 2016-08-16 Kyphon SÀRL Activatable devices containing a chemonucleolysis agent
JO3375B1 (ar) 2010-11-08 2019-03-13 Regeneron Pharma أجسام مضادة بشرية للجين a1 الشبيه بعامل النخر الورمي (tl1a)
WO2012075447A2 (fr) 2010-12-03 2012-06-07 Warsaw Orthopedic, Inc. Compositions et méthodes d'administration de clonidine et de bupivacaïne en direction d'un tissu cible
WO2012075451A2 (fr) 2010-12-03 2012-06-07 Warsaw Orthopedic, Inc. Composés de clonidine et gaba dans un véhicule de type polymère biodégradable
US9060978B2 (en) 2011-01-24 2015-06-23 Warsaw Orthopedic, Inc. Method for treating an intervertebral disc disorder by administering a dominant negative tumor necrosis factor antagonist
US9717779B2 (en) 2011-01-31 2017-08-01 Warsaw Orthopedic, Inc. Implantable matrix having optimum ligand concentrations
CN103492416A (zh) 2011-04-15 2014-01-01 默克专利股份公司 用于癌症中使用的抗il-1r1抑制剂
US9511077B2 (en) 2011-04-25 2016-12-06 Warsaw Orthopedic, Inc. Medical devices and methods comprising an anabolic agent for wound healing
US9592243B2 (en) 2011-04-25 2017-03-14 Warsaw Orthopedic, Inc. Medical devices and methods comprising an anabolic agent for treatment of an injury
US9132194B2 (en) 2011-07-12 2015-09-15 Warsaw Orthopedic, Inc. Medical devices and methods comprising an adhesive sheet containing a drug depot
US9205241B2 (en) 2011-07-12 2015-12-08 Warsaw Orthopedic, Inc. Medical devices and methods comprising an adhesive material
JP6177249B2 (ja) 2011-11-14 2017-08-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｇｄｆ８及び／又はアクチビンａに特異的に拮抗することによって筋肉量及び筋力を増加させる組成物及び方法
RU2768492C2 (ru) 2011-11-18 2022-03-24 Ридженерон Фармасьютикалз, Инк. Полимерные белковые микрочастицы
EP2804623B1 (fr) * 2012-01-12 2019-08-07 Bioverativ Therapeutics Inc. Facteur viii chimérique et polypeptides et leurs utilisations
US9511018B2 (en) 2012-04-05 2016-12-06 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable matrix
US8735504B2 (en) 2012-05-02 2014-05-27 Warsaw Orthopedic, Inc. Methods for preparing polymers having low residual monomer content
CN103509100B (zh) * 2012-06-15 2017-10-27 上海百迈博制药有限公司 一种白细胞介素‑1受体拮抗剂突变体
IL312711A (en) 2012-08-21 2024-07-01 Regeneron Pharma Methods for the treatment or prevention of asthma through the administration of an antagonist to 4R-IL
JO3462B1 (ar) 2012-08-22 2020-07-05 Regeneron Pharma أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
WO2014035361A1 (fr) * 2012-08-26 2014-03-06 R-PHARM, CJSC (Closed Joint Stock Company) Composition d'inhibiteur de l'il-1β et son utilisation
KR102576903B1 (ko) 2012-09-07 2023-09-13 리제너론 파아마슈티컬스, 인크. Ｉｌ-4ｒ 길항제 투여로 아토피성 피부염을 치료하는 방법
TW202423993A (zh) 2012-11-14 2024-06-16 美商再生元醫藥公司 重組細胞表面捕捉蛋白質
US9066853B2 (en) 2013-01-15 2015-06-30 Warsaw Orthopedic, Inc. Clonidine compounds in a biodegradable fiber
EP4050019A1 (fr) 2013-02-15 2022-08-31 R-Pharm International, LLC Composition d'inhibiteur d'il-1beta et utilisation correspondante
CN107693781B (zh) 2013-03-13 2021-11-09 巴扎德制药公司 用于眼部递送的嵌合细胞因子制剂
EA201591754A1 (ru) 2013-03-14 2016-01-29 Ридженерон Фармасьютикалз, Инк. Человеческие антитела к na1.7
US10143725B2 (en) 2013-03-15 2018-12-04 Biomet Biologics, Llc Treatment of pain using protein solutions
US9895418B2 (en) 2013-03-15 2018-02-20 Biomet Biologics, Llc Treatment of peripheral vascular disease using protein solutions
TWI828269B (zh) 2013-03-15 2024-01-01 美商百歐維拉提夫治療公司 因子ix多肽調配物
US9878011B2 (en) 2013-03-15 2018-01-30 Biomet Biologics, Llc Treatment of inflammatory respiratory disease using biological solutions
US20140271589A1 (en) 2013-03-15 2014-09-18 Biomet Biologics, Llc Treatment of collagen defects using protein solutions
US9950035B2 (en) 2013-03-15 2018-04-24 Biomet Biologics, Llc Methods and non-immunogenic compositions for treating inflammatory disorders
PE20151673A1 (es) 2013-03-15 2015-11-27 Genentech Inc POLIPEPTIDOS DE IL-22 Y PROTEINAS DE FUSION DE IL-22 Fc Y METODOS DE USO
US9758806B2 (en) 2013-03-15 2017-09-12 Biomet Biologics, Llc Acellular compositions for treating inflammatory disorders
US10208095B2 (en) 2013-03-15 2019-02-19 Biomet Manufacturing, Llc Methods for making cytokine compositions from tissues using non-centrifugal methods
AU2014274044B2 (en) * 2013-05-31 2019-06-27 Regeneron Pharmaceuticals, Inc. Methods of using IL-1 antagonists to treat Alzheimer's Disease
KR20210132232A (ko) 2013-06-21 2021-11-03 사노피 바이오테크놀로지 Il-4r 길항제를 투여함에 의한 비용종증의 치료 방법
EP3074507B1 (fr) 2013-11-26 2022-01-05 Biomet Biologics, LLC Procédés de médiation des phénotypes macrophagiques
SG11201605242YA (en) 2014-01-10 2016-07-28 Biogen Ma Inc Factor viii chimeric proteins and uses thereof
IL315136A (en) 2014-02-21 2024-10-01 Sanofi Biotechnology Methods for treating or preventing asthma by administering an il-4rantagonist
WO2015147789A1 (fr) * 2014-03-24 2015-10-01 R-Pharm Overseas, Inc. Inhibiteur dérivé d'il1-r1 humain inhibitant il-1 b
US12180264B2 (en) 2014-03-24 2024-12-31 R-Pharm Overseas, Inc. IL1-R1 derived inhibitor of IL-1β and use thereof
US9775978B2 (en) 2014-07-25 2017-10-03 Warsaw Orthopedic, Inc. Drug delivery device and methods having a retaining member
US9764122B2 (en) 2014-07-25 2017-09-19 Warsaw Orthopedic, Inc. Drug delivery device and methods having an occluding member
US10441635B2 (en) 2014-11-10 2019-10-15 Biomet Biologics, Llc Methods of treating pain using protein solutions
WO2016077675A1 (fr) 2014-11-14 2016-05-19 Sanofi Biotechnology Méthodes de traitement de la sinusite chronique avec polypose nasale par administration d'un antagoniste d'il-4r
SG11201706293XA (en) 2015-02-04 2017-09-28 Hoffmann La Roche Tau antisense oligomers and uses thereof
EP3254104B1 (fr) 2015-02-04 2021-08-25 Bristol-Myers Squibb Company Procédés de sélection de molécules thérapeutiques
GB201503453D0 (en) 2015-03-01 2015-04-15 Jain Arjun Endothelin-1"sponge"
AU2016227458A1 (en) * 2015-03-01 2018-08-02 Arjun Jain Endothelin-1 receptor based endothelin-1 sponge
US9763800B2 (en) 2015-03-18 2017-09-19 Biomet C. V. Implant configured for hammertoe and small bone fixation
MA41919A (fr) 2015-04-06 2018-02-13 Acceleron Pharma Inc Hétéromultimères alk4:actriib et leurs utilisations
BR112017021510A2 (pt) 2015-04-06 2018-07-03 Acceleron Pharma Inc heteromultímeros do receptor tipo i e tipo ii da superfamília tgf-beta e sua utilização
WO2016168613A1 (fr) 2015-04-15 2016-10-20 Regeneron Pharmaceuticals, Inc. Méthode pour augmenter la résistance et la fonctionnalité avec des inhibiteurs de gdf-8
US10076650B2 (en) 2015-11-23 2018-09-18 Warsaw Orthopedic, Inc. Enhanced stylet for drug depot injector
EA202192290A1 (ru) 2015-12-16 2022-02-28 Ридженерон Фармасьютикалз, Инк. Композиции и способы получения белковых микрочастиц
EP3439741B1 (fr) 2016-04-06 2026-05-20 Acceleron Pharma Inc Hétéromultimères actriib:alk7 pour la réduction thérapeutique du poids corporel
USD802755S1 (en) 2016-06-23 2017-11-14 Warsaw Orthopedic, Inc. Drug pellet cartridge
IL264640B2 (en) 2016-08-18 2024-03-01 Regeneron Pharma Assay for determining potential to self-association of a protein using concentration-dependent self-interaction nanoparticle spectroscopy
US11771743B2 (en) 2016-09-01 2023-10-03 Regeneron Pharmaceuticals, Inc. Methods for preventing or treating allergy by administering an IL-4R antagonist
WO2018067879A1 (fr) 2016-10-05 2018-04-12 Acceleron Pharma Inc. Hétéromultimères alk4:actriib et leurs utilisations
IL310367A (en) 2016-10-07 2024-03-01 Regeneron Pharma A stable protein at room temperature that has been lyophilized
US10434261B2 (en) 2016-11-08 2019-10-08 Warsaw Orthopedic, Inc. Drug pellet delivery system and method
KR20190090820A (ko) 2016-11-29 2019-08-02 리제너론 파아마슈티컬스, 인크. 오피오이드 중독 방지를 위한 약학 조성물
TWI857389B (zh) 2016-12-01 2024-10-01 美商再生元醫藥公司 治療發炎症狀的方法
MX2019006444A (es) 2016-12-02 2019-10-30 Bioverativ Therapeutics Inc Métodos de tratamiento de artropatía hemofílica utilizando factores de coagulación quiméricos.
EP3655961A4 (fr) * 2017-07-17 2021-09-01 Massachusetts Institute of Technology Atlas de cellules de tissus barrières sains et malades
EP3703818B1 (fr) 2017-10-30 2023-11-01 Sanofi Biotechnology Antagoniste d'il-4r pour son utilisation dans le traitement ou la prévention de l'asthme
KR20200128125A (ko) 2018-03-01 2020-11-11 리제너론 파아마슈티컬스, 인크. 신체 조성을 변경하기 위한 방법
SI3793588T1 (sl) 2018-05-18 2025-07-31 Bioverativ Therapeutics Inc. Postopki zdravljenja hemofilije A
CA3108697A1 (fr) 2018-08-10 2020-02-13 Regeneron Pharmaceuticals, Inc. Composition pharmaceutique pour le traitement sur et efficace de la douleur du genou et/ou de la hanche
SG11202109002XA (en) 2019-03-21 2021-09-29 Regeneron Pharma Combination of il-4/il-13 pathway inhibitors and plasma cell ablation for treating allergy
KR20220004708A (ko) 2019-05-01 2022-01-11 사노피 바이오테크놀로지 Il-33 길항제를 투여하여 천식을 치료 또는 예방하는 방법
CA3147436A1 (fr) 2019-07-16 2021-01-21 Sanofi Biotechnology Methodes de traitement ou de prevention de l'asthme par administration d'un antagoniste d'il-4r
US20210230265A1 (en) 2019-12-06 2021-07-29 Sanofi Biotechnology Methods for treating copd by administering an il-33 antagonist
CA3162507A1 (fr) 2019-12-23 2021-07-01 Helene Goulaouic Methodes de traitement ou de prevention de l'asthme allergique par administration d'un antagoniste d'il-33 et/ou d'un antagoniste d'il-4r
JP2023515270A (ja) 2020-04-21 2023-04-12 テンパス・ラボズ・インコーポレイテッド Ｔｃｒ／ｂｃｒプロファイリング
MX2023003942A (es) 2020-10-05 2023-06-02 Sanofi Biotechnology Metodos para el tratamiento del asma en sujetos pediatricos mediante la administracion de un antagonista del il-4r.
TW202607038A (zh) 2020-10-19 2026-02-16 美商碩騰服務公司 犬及貓抑瘤素Ｍ受體β之抗體及其用途
MX2023006077A (es) 2020-11-25 2023-06-06 Regeneron Pharma Formulaciones de liberacion sostenida mediante emulsificacion por membrana no acuosa.
TW202233827A (zh) 2021-01-20 2022-09-01 美商再生元醫藥公司 改良細胞培養中蛋白質效價的方法
AR125585A1 (es) 2021-03-03 2023-08-02 Regeneron Pharma Sistemas y métodos para cuantificar y modificar la viscosidad de proteínas
BR112023024984A2 (pt) 2021-06-01 2024-02-20 Regeneron Pharma Tampão de amostra de eletroforese aquosa, método para identificar contaminantes ou impurezas em uma amostra de droga proteica, e, kit
WO2023009437A1 (fr) 2021-07-26 2023-02-02 Sanofi Biotechnology Méthodes de traitement de l'urticaire spontanée chronique par administration d'un antagoniste de l'il-4r
TW202326138A (zh) 2021-09-08 2023-07-01 美商再生元醫藥公司 用於定量抗體及其他含Ｆｃ蛋白之高通量及基於質譜之方法
US20230183362A1 (en) 2021-10-20 2023-06-15 Sanofi Biotechnology Methods for treating prurigo nodularis by administering an il-4r antagonist
MX2024005090A (es) 2021-10-26 2024-07-19 Regeneron Pharma Sistemas y metodos para generar agua de laboratorio y distribuir agua de laboratorio a diferentes temperaturas.
US20250011408A1 (en) 2021-11-19 2025-01-09 Regeneron Pharmaceuticals, Inc. Methods and compositions for reducing centralized pain
AU2022445159A1 (en) 2022-03-10 2024-09-26 Buzzard Pharmaceuticals AB Inhibitor of interleukin-1 receptor type 1 for use in the treatment of cancer
WO2023212586A1 (fr) 2022-04-27 2023-11-02 Regeneron Pharmaceuticals, Inc. Procédés de sélection de patients pour le traitement avec un antagoniste du ngf
WO2024047021A1 (fr) 2022-08-29 2024-03-07 Sanofi Méthodes de traitement de l'urticaire au froid inductible chronique par administration d'un antagoniste de l'il-4r
WO2024158961A1 (fr) 2023-01-25 2024-08-02 Regeneron Pharmaceuticals, Inc. Caractérisation basée sur la spectrométrie de masse d'anticorps co-exprimés in vivo
WO2024163708A1 (fr) 2023-02-01 2024-08-08 Regeneron Pharmaceuticals, Inc. Fractionnement en continu à flux asymétrique avec spectrométrie de masse pour analyse biomacromoléculaire
CN116286844A (zh) 2023-02-13 2023-06-23 浙江大学 人IL-1R1和人IL-1RAcP多肽片段组合的同源二聚体蛋白质与用途
US20240280551A1 (en) 2023-02-22 2024-08-22 Regeneron Pharmaceuticals, Inc. System suitability parameters and column aging
JP2026507151A (ja) * 2023-02-28 2026-02-27 コディアック サイエンシーズ インコーポレイテッド 多価トラップ－抗体融合体
EP4683942A1 (fr) 2023-03-22 2026-01-28 Sanofi Biotechnology Méthodes de traitement de la bronchopneumopathie chronique obstructive (bpco) par administration d'un antagoniste d'il-4r
TW202508625A (zh) 2023-05-01 2025-03-01 美商再生元醫藥公司 使用苯酚或苯甲醇之多劑量抗體藥物產品
CN121794393A (zh) 2023-09-07 2026-04-03 里珍纳龙药品有限公司 经共价表面修饰的腺相关病毒的生产和纯化
CN121925272A (zh) 2023-09-29 2026-04-24 瑞泽恩制药公司 利用受控成核进行冻干
TW202540433A (zh) 2023-11-21 2025-10-16 美商再生元醫藥公司 藉由活體外接合產生共價表面修飾之腺相關病毒及共價表面修飾的腺相關病毒之純化
WO2025116768A1 (fr) * 2023-11-29 2025-06-05 Общество с ограниченной ответственностью "Пальмира Биофарма" Protéine fusionnée comprenant un fragment il-6r et un fc-fragment igg4
WO2025175164A1 (fr) 2024-02-16 2025-08-21 Regeneron Pharmaceuticals, Inc. Procédés de production de substances médicamenteuses formulées concentrées comprenant des protéines, et substance médicamenteuse formulée concentrée fabriquée par les procédés
WO2025194043A1 (fr) 2024-03-15 2025-09-18 Regeneron Pharmaceuticals, Inc. Polysorbate et polyoxyéthylène sorbitane utilisés en tant qu'excipients pour formulations de protéines stables
TW202607027A (zh) 2024-04-15 2026-02-16 法商賽諾菲生物技術公司 藉由施用ｉｌ－４ｒ拮抗劑治療慢性鼻竇炎不伴鼻息肉之方法
WO2026025028A1 (fr) 2024-07-26 2026-01-29 Regeneron Pharmaceuticals, Inc. Procédés de fabrication de formulations protéiques à concentration ultra-élevée par lyophilisation
WO2026059949A1 (fr) 2024-09-10 2026-03-19 Sanofi Biotechnology Méthodes de traitement du prurit chronique d'origine inconnue (cpuo) par administration d'un antagoniste d'il-4r
WO2026060350A1 (fr) 2024-09-13 2026-03-19 Regeneron Pharmaceuticals, Inc. Procédés d'amélioration de la photostabilité et de contrôle de la formation d'espèces hmw dans des formulations biologiques, et formulations biologiques produites par les procédés
WO2026076201A2 (fr) 2024-10-03 2026-04-09 Regeneron Pharmaceuticals, Inc. Systèmes et procédés de production de protéines thérapeutiques par filtration tangentielle à passage unique pour la concentration en ligne et la réduction volumique de groupes de production

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE169030T1 (de) 1990-06-28 1998-08-15 Hoechst Ag Fusionsproteine mit immunglobulinanteilen, ihre herstellung und verwendung
EP0533006A1 (fr) 1991-09-18 1993-03-24 F.Hoffmann-La Roche & Co. Aktiengesellschaft Chimères constituées du récepteur de l'interleukine 5 et de polypeptides d'immunoglobulines
WO1993019163A1 (fr) 1992-03-18 1993-09-30 Yeda Research And Development Co, Ltd. Genes de recepteurs chimeres et cellules transformees au moyen desdits genes
US8211422B2 (en) 1992-03-18 2012-07-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Chimeric receptor genes and cells transformed therewith
EP0670730B1 (fr) 1992-03-30 2003-06-04 Immunex Corporation Proteine de fusion comprenant deux recepteurs du facteur de necrose tumorale
WO1994022914A1 (fr) 1993-04-06 1994-10-13 Fred Hutchinson Cancer Research Center Recepteurs de cytokine chimeriques dans des lymphocytes
EP0716703A1 (fr) 1993-09-03 1996-06-19 PRENDERGAST, Kenneth, Francis Compositions proteiques de fusion contenant la proteine de liaison a la glycophorine (gbp 130)
US5470952A (en) * 1993-10-20 1995-11-28 Regeneron Pharmaceuticals, Inc. CNTF and IL-6 antagonists
AU3830895A (en) 1994-10-07 1996-05-02 Amgen Boulder Inc. Dimeric il-4 inhibitors
US5837544A (en) 1995-02-02 1998-11-17 Cell Genesys, Inc. Method of inducing a cell to proliferate using a chimeric receptor comprising janus kinase
US5837816A (en) 1995-05-10 1998-11-17 Chiron Corporation Interleukin-2 receptor subunit ectodomain fusion protein comprising a leucine zipper domain
US5710023A (en) 1996-03-01 1998-01-20 Genetics Institute, Inc. IL-13 cytokine receptor chain
CA2273852C (fr) * 1996-12-06 2009-09-29 Amgen Inc. Therapie combinee utilisant un inhibiteur de l'il-1 pour traiter les maladies induites par l'il-1
US5945511A (en) * 1997-02-20 1999-08-31 Zymogenetics, Inc. Class II cytokine receptor
ATE272114T1 (de) 1998-01-23 2004-08-15 Immunex Corp Rezeptoren für il-18
US6472179B2 (en) * 1998-09-25 2002-10-29 Regeneron Pharmaceuticals, Inc. Receptor based antagonists and methods of making and using
US6927044B2 (en) * 1998-09-25 2005-08-09 Regeneron Pharmaceuticals, Inc. IL-1 receptor based cytokine traps
US6610750B1 (en) * 2000-09-15 2003-08-26 Laboratoires Negma Treatment of osteoarthritis
WO2004100987A2 (fr) * 2003-05-06 2004-11-25 Regeneron Pharmaceuticals, Inc. Procede d'utilisation d'antagonistes de l'il1 pour le traitement d'hyperplasie neointimale

Also Published As

Publication number Publication date
IL168050A (en) 2010-12-30
US6927044B2 (en) 2005-08-09
AU2003284895A1 (en) 2004-05-25
BR0315652A (pt) 2005-08-30
ATE420970T1 (de) 2009-01-15
DE60325892D1 (de) 2009-03-05
BRPI0315652B8 (pt) 2021-05-25
CA2502385C (fr) 2012-06-12
WO2004039951A2 (fr) 2004-05-13
US20050197293A1 (en) 2005-09-08
US7361350B2 (en) 2008-04-22
CN1878871B (zh) 2011-08-03
EP1572967B1 (fr) 2009-01-14
WO2004039951A3 (fr) 2006-08-03
ES2320338T3 (es) 2009-05-21
CA2502385A1 (fr) 2004-05-13
DK1572967T3 (da) 2009-03-16
CY2010010I1 (el) 2012-01-25
SI1572967T1 (sl) 2009-06-30
CY1110675T1 (el) 2012-01-25
BRPI0315652B1 (pt) 2018-02-06
US20030143697A1 (en) 2003-07-31
JP2006518985A (ja) 2006-08-24
EP1572967A2 (fr) 2005-09-14
JP4387309B2 (ja) 2009-12-16
US7927583B2 (en) 2011-04-19
MXPA05004333A (es) 2005-08-03
EP1572967A4 (fr) 2007-05-02
CY2010010I2 (el) 2012-01-25
US20050222033A1 (en) 2005-10-06
AU2003284895B2 (en) 2009-11-05
PT1572967E (pt) 2009-03-05
HK1080511A1 (en) 2006-04-28
US7417134B2 (en) 2008-08-26
US20090010879A1 (en) 2009-01-08
CN1878871A (zh) 2006-12-13

Similar Documents

Publication Publication Date Title
DE60325892D1 (de) Stellungs- und verwendungsverfahren
ATE259782T1 (de) N-cyanomethylamide als protease-inhibitoren
IL195338A (en) An antibody comprising an FC variant containing amino acid replaces d or e at position 239, a medicament containing it and its use
MY134129A (en) Polymorphs of an epothilone analog
BR0116452A (pt) Composto, composição farmacêutica, uso de um composto
HK1039110A1 (zh) 以新颖的合成物及组分作为蛋白酶抑制剂
ID26984A (id) Senyawa-senyawa sulfonamida sebagai antagonis reseptor angiotensin endotelin ganda
ITUD20030092A1 (it) Protesi per l'articolazione della spalla.
EA200300937A1 (ru) Оральная фармацевтическая композиция цефподоксима проксетила
DE50307984D1 (de) Streptavidin-Bindungspeptid
WO2001068645A3 (fr) Composes et compositions agissant comme inhibiteurs de proteines
EA200300392A1 (ru) Производные пиперазина с мостиковой связью
CY1106376T1 (el) Δικυκλικα παραγωγα των αμινο-πυραζινονων, μεθοδος παρασκευης τους και οι φαρμακευτικες συνθεσεις που τα πepιεχουν
TR200001102T2 (tr) İkameli tetrahidropirimidinen türevleri, üretimleri ve kullanımları.
ATE522230T1 (de) Biphenyle als bilderzeugungsmittel bei der alzheimerschen krankheit
IL162314A0 (en) Use of pyridine-2,4-dicarboxylic acid diamides andof pyrimidine-4,6-dicarboxylic acid diamides for selective collagenase inhibition
AU2003271811A8 (en) Novel derivatives of 4,4'-dithiobis-(3-aminobutane-1-sulphonates) and compositions containing same
DE60134735D1 (de) Neue neurokinin-antagonisten zum gebrauch als arzneimittel
TW200505906A (en) Selective mmp-13 inhibitors
BR0316544A (pt) Compostos calcilìticos
PT1150716E (pt) Composicao farmaceutica de proteinas hedgehog hidrofobicamente modificadas e sua utilizacao
EP1452522A3 (fr) Nouveaux composés et composiitons comme inhibiteurs de proteases
HUP0102540A2 (hu) Új angiotenzin-receptor, eljárás előállítására és alkalmazása
ITVR20020030A0 (it) Miscela per polvere di saldatura, nonche procedimento per l'impiego di detta miscela.
CR20120385A (es) Nuevos pirrolocarbazoles fusionados (divisional exp. 8519)